Neuroendocrinology News

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.

Adults diagnosed with endogenous Cushing’s syndrome have a higher risk for developing cancer compared with controls without the condition, according to data published in the European Journal of Endocrinology.

Some types of endocrine-disrupting chemicals may act as kisspeptin or gonadotropin-releasing hormone receptor agonists and could induce early puberty for children, according to in vitro findings published in Endocrinology.

Having high insulin-like growth factor I levels over a longer duration increased risk for cancer among adults with acromegaly, but not for those with nonfunction pituitary adenoma, according to study data.

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.

BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.

BOSTON — Long-term osilodrostat therapy may improve symptoms of comorbid cardiometabolic disorders such as hypertension and diabetes for adults with Cushing’s disease, according to data presented at ENDO 2024.